149 related articles for article (PubMed ID: 31218784)
41. Paget's disease of the nipple: a copy number of the genes ERBB2 and CCND1 versus expression of the proteins ERBB-2 and cyclin D1.
Mrhalova M; Kodet R
Neoplasma; 2003; 50(6):396-402. PubMed ID: 14689059
[TBL] [Abstract][Full Text] [Related]
42. Unknown partner for USP6 and unusual SS18 rearrangement detected by fluorescence in situ hybridization in a solid aneurysmal bone cyst.
Geiersbach K; Rector LS; Sederberg M; Hooker A; Randall RL; Schiffman JD; South ST
Cancer Genet; 2011 Apr; 204(4):195-202. PubMed ID: 21536237
[TBL] [Abstract][Full Text] [Related]
43. Early genetic events provide the basis for a clinical classification of multiple myeloma.
Kuehl WM; Bergsagel PL
Hematology Am Soc Hematol Educ Program; 2005; ():346-52. PubMed ID: 16304402
[TBL] [Abstract][Full Text] [Related]
44. ALK+ lung adenocarcinoma in never smokers and long-term ex-smokers: prevalence and detection by immunohistochemistry and fluorescence in situ hybridization.
Williams AS; Greer W; Bethune D; Craddock KJ; Flowerdew G; Xu Z
Virchows Arch; 2016 Nov; 469(5):533-540. PubMed ID: 27562706
[TBL] [Abstract][Full Text] [Related]
45. Detection of ROS1 gene rearrangement in lung adenocarcinoma: comparison of IHC, FISH and real-time RT-PCR.
Shan L; Lian F; Guo L; Qiu T; Ling Y; Ying J; Lin D
PLoS One; 2015; 10(3):e0120422. PubMed ID: 25742289
[TBL] [Abstract][Full Text] [Related]
46. Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously Reported Gene Expression Profile Patterns in Plasma Cell Myeloma.
Mansoor A; Akhter A; Pournazari P; Mahe E; Shariff S; Farooq F; Elyamany G; Shahbani-Rad MT; Rashid-Kolvear F
Appl Immunohistochem Mol Morphol; 2015; 23(5):327-33. PubMed ID: 25265432
[TBL] [Abstract][Full Text] [Related]
47. CCND1 rearrangements and cyclin D1 overexpression in renal oncocytomas: frequency, clinicopathologic features, and utility in differentiation from chromophobe renal cell carcinoma.
Sukov WR; Ketterling RP; Lager DJ; Carlson AW; Sinnwell JP; Chow GK; Jenkins RB; Cheville JC
Hum Pathol; 2009 Sep; 40(9):1296-303. PubMed ID: 19386349
[TBL] [Abstract][Full Text] [Related]
48. Plasma cell myeloma.
Lin P
Hematol Oncol Clin North Am; 2009 Aug; 23(4):709-27. PubMed ID: 19577166
[TBL] [Abstract][Full Text] [Related]
49. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer.
Pekar-Zlotin M; Hirsch FR; Soussan-Gutman L; Ilouze M; Dvir A; Boyle T; Wynes M; Miller VA; Lipson D; Palmer GA; Ali SM; Dekel S; Brenner R; Bunn PA; Peled N
Oncologist; 2015 Mar; 20(3):316-22. PubMed ID: 25721120
[TBL] [Abstract][Full Text] [Related]
50. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
[TBL] [Abstract][Full Text] [Related]
51. Characterization of c-Maf transcription factor in normal and neoplastic hematolymphoid tissue and its relevance in plasma cell neoplasia.
Natkunam Y; Tedoldi S; Paterson JC; Zhao S; Rodriguez-Justo M; Beck AH; Siebert R; Mason DY; Marafioti T
Am J Clin Pathol; 2009 Sep; 132(3):361-71. PubMed ID: 19687312
[TBL] [Abstract][Full Text] [Related]
52. A comparative analysis of immunohistochemistry and fluorescent
Wagle PB; Jambhekar NA; Kumar R; Prabhash K; Pramesh CS; Desai SB; Noronha V; Karimundackal G; Shah A; Joshi A; Laskar SG; Jiwnani S; Pai T; Agarwal JP
Indian J Cancer; 2017; 54(1):148-154. PubMed ID: 29199679
[TBL] [Abstract][Full Text] [Related]
53. High prevalence of immunoglobulin light chain gene aberrations as revealed by FISH in multiple myeloma and MGUS.
Türkmen S; Binder A; Gerlach A; Niehage S; Theodora Melissari M; Inandiklioglu N; Dörken B; Burmeister T
Genes Chromosomes Cancer; 2014 Aug; 53(8):650-6. PubMed ID: 24729354
[TBL] [Abstract][Full Text] [Related]
54. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma.
Ying J; Guo L; Qiu T; Shan L; Ling Y; Liu X; Lu N
Ann Oncol; 2013 Oct; 24(10):2589-2593. PubMed ID: 23904459
[TBL] [Abstract][Full Text] [Related]
55. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.
Kim H; Yoo SB; Choe JY; Paik JH; Xu X; Nitta H; Zhang W; Grogan TM; Lee CT; Jheon S; Chung JH
J Thorac Oncol; 2011 Aug; 6(8):1359-66. PubMed ID: 21587085
[TBL] [Abstract][Full Text] [Related]
56. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer.
Jacobs TW; Gown AM; Yaziji H; Barnes MJ; Schnitt SJ
J Clin Oncol; 1999 Jul; 17(7):1974-82. PubMed ID: 10561247
[TBL] [Abstract][Full Text] [Related]
57. Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue.
Park IH; Kwon Y; Ro JY; Lee KS; Ro J
Breast Cancer Res Treat; 2010 Aug; 123(1):125-8. PubMed ID: 19916047
[TBL] [Abstract][Full Text] [Related]
58. Atypical IgM multiple myeloma with deletion of c-MAF.
Juárez Salcedo LM; López Rubio M; Gil Fernández JJ; Garcia-Suarez J; Magro E; Arranz E; Gutiérrez Jomarrón I; Marcellini Antonio S; Blasco A; Burgaleta C
Int J Lab Hematol; 2015 Oct; 37(5):686-9. PubMed ID: 25996654
[TBL] [Abstract][Full Text] [Related]
59. [HER-2 overexpression and gene amplification of advanced breast cancers determined by fluorescence in situ hybridization in fine needle aspiration specimens].
Zhang Z; Zhao L; Guo H; Guo L; Ling Y; Xu X; Zhao H; Pan Q
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):183-7. PubMed ID: 24785277
[TBL] [Abstract][Full Text] [Related]
60. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.
Agnelli L; Bicciato S; Mattioli M; Fabris S; Intini D; Verdelli D; Baldini L; Morabito F; Callea V; Lombardi L; Neri A
J Clin Oncol; 2005 Oct; 23(29):7296-306. PubMed ID: 16129847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
